YCMGA
GBT

York Capital Management Global Advisors’s Global Blood Therapeutics, Inc. GBT Stock Holding History

York Capital Management Global Advisors’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-115,000
Closed -$4.24M – 84
2017
Q1 		$4.24M Buy
+115,000
New +$2.9M 0.1% 64

Other funds holding GBT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

York Capital Management Global Advisors's GBT Position: Q2 2017 in Review

York Capital Management Global Advisors sold out of Global Blood Therapeutics, Inc. (GBT) in Q2 2017, closing a stake of 115,000 shares — an estimated $4.24M sold.

York Capital Management Global Advisors first reported a position in GBT in Q1 2017 and held it in 1 quarter. The position peaked at $4.24M in Q1 2017. 134 funds tracked by Wall St. Rank hold GBT as of Q2 2017.

  • York Capital Management Global Advisors reported no remaining Global Blood Therapeutics, Inc. position as of Q2 2017 after selling out during the quarter.
  • York Capital Management Global Advisors sold 115,000 Global Blood Therapeutics, Inc. shares in Q2 2017, an estimated $4.24M.
  • York Capital Management Global Advisors first reported a position in Global Blood Therapeutics, Inc. in Q1 2017 and held it in 1 quarter.
  • York Capital Management Global Advisors's Global Blood Therapeutics, Inc. position peaked at $4.24M in Q1 2017.
  • 134 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q2 2017.

Based on York Capital Management Global Advisors's 13F filing for Q2 2017, filed 14 Aug 2017.